RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Human telomerase reverse transcriptase (hTERT) is a key biomarker and therapeutic target in various cancers, including glioblastoma.
• Elevated telomerase activity is a hallmark of cancer, making hTERT a critical focus for targeted therapies.

Purpose of the Study:

• To investigate the expression of hTERT in glioblastoma.
• To evaluate the efficacy of two novel small interfering RNAs (siRNAs) in downregulating hTERT expression and its impact on glioblastoma cell viability.

Main Methods:

• Analysis of hTERT expression in patient glioblastoma data.
• In vitro transfection of LN18 glioblastoma cells with siRNAs targeting hTERT.
• Assessment of cell viability using MTT and trypan blue exclusion assays.
• Flow cytometry to analyze apoptosis.
• Confirmation of mRNA and protein downregulation via immunoblotting.

Main Results:

• Increased hTERT expression was observed in glioblastoma patient data, correlating with carcinogenesis.
• siRNA transfection resulted in significant glioblastoma cell death (p < 0.05).
• Flow cytometry confirmed increased early and late apoptosis.
• siRNA1 and siRNA2 reduced hTERT mRNA by 45% and 39%, respectively.
• Immunoblotting confirmed significant downregulation of hTERT protein levels (p < 0.05).

Conclusions:

• Both novel siRNAs effectively downregulate hTERT at both mRNA and protein levels in glioblastoma cells.
• Targeting hTERT with siRNAs decreases glioblastoma cell viability and proliferation.
• siRNA-mediated hTERT downregulation represents a promising therapeutic strategy for glioblastoma.